[go: up one dir, main page]

SE9301877D0 - In situ gel for therapeutic use - Google Patents

In situ gel for therapeutic use

Info

Publication number
SE9301877D0
SE9301877D0 SE9301877A SE9301877A SE9301877D0 SE 9301877 D0 SE9301877 D0 SE 9301877D0 SE 9301877 A SE9301877 A SE 9301877A SE 9301877 A SE9301877 A SE 9301877A SE 9301877 D0 SE9301877 D0 SE 9301877D0
Authority
SE
Sweden
Prior art keywords
therapeutic use
situ gel
liquid
situ
drugs
Prior art date
Application number
SE9301877A
Other languages
English (en)
Inventor
*Carlfors Johan
*Edsman Katarina
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9301877A priority Critical patent/SE9301877D0/sv
Publication of SE9301877D0 publication Critical patent/SE9301877D0/sv
Priority to JP7500555A priority patent/JPH08510731A/ja
Priority to EP94917868A priority patent/EP0706372A1/en
Priority to AU69405/94A priority patent/AU6940594A/en
Priority to CA 2164113 priority patent/CA2164113A1/en
Priority to PCT/SE1994/000522 priority patent/WO1994027578A1/en

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9301877A 1993-06-02 1993-06-02 In situ gel for therapeutic use SE9301877D0 (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE9301877A SE9301877D0 (sv) 1993-06-02 1993-06-02 In situ gel for therapeutic use
JP7500555A JPH08510731A (ja) 1993-06-02 1994-06-01 治療使用のためのその場で生成するゲル
EP94917868A EP0706372A1 (en) 1993-06-02 1994-06-01 In situ gel for therapeutic use
AU69405/94A AU6940594A (en) 1993-06-02 1994-06-01 In situ gel for therapeutic use
CA 2164113 CA2164113A1 (en) 1993-06-02 1994-06-01 In situ gel for therapeutic use
PCT/SE1994/000522 WO1994027578A1 (en) 1993-06-02 1994-06-01 In situ gel for therapeutic use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9301877A SE9301877D0 (sv) 1993-06-02 1993-06-02 In situ gel for therapeutic use

Publications (1)

Publication Number Publication Date
SE9301877D0 true SE9301877D0 (sv) 1993-06-02

Family

ID=20390132

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9301877A SE9301877D0 (sv) 1993-06-02 1993-06-02 In situ gel for therapeutic use

Country Status (6)

Country Link
EP (1) EP0706372A1 (sv)
JP (1) JPH08510731A (sv)
AU (1) AU6940594A (sv)
CA (1) CA2164113A1 (sv)
SE (1) SE9301877D0 (sv)
WO (1) WO1994027578A1 (sv)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2287597A (en) * 1996-03-13 1997-10-01 Laboratoires Merck Sharp & Dohme - Chibret Snc Ophthalmological composition of the type which undergoes liquid-gel phase tr ansition
FR2746014B1 (fr) * 1996-03-13 1999-01-08 Composition ophtalmologique du type subissant une transition de phase liquide-gel
FR2754712B1 (fr) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
AU5453198A (en) * 1996-11-29 1998-06-22 Monsanto Company Lubricious self-standing (intact) gel for oral delivery of biologically-active ingredients
JP2004189731A (ja) * 2002-11-26 2004-07-08 Taisho Pharmaceut Co Ltd 点鼻剤
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
JP5304108B2 (ja) * 2007-08-30 2013-10-02 大正製薬株式会社 点眼剤
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US10398742B2 (en) 2014-12-15 2019-09-03 The Johns Hopkins University CVS transplantation for treatment of bacterial vaginosis
EP3250184B1 (en) 2015-01-27 2024-12-18 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN109260146A (zh) * 2018-10-12 2019-01-25 广州大光制药有限公司 地夸磷索钠眼用即用型凝胶滴眼液及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
FR2657018A1 (fr) * 1990-01-12 1991-07-19 Merck Sharp & Dohme Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
CA2040460C (en) * 1990-05-01 1997-06-10 Tacey X. Viegas Drug delivery with thermoreversible gels
JP2594486B2 (ja) * 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物

Also Published As

Publication number Publication date
EP0706372A1 (en) 1996-04-17
WO1994027578A1 (en) 1994-12-08
CA2164113A1 (en) 1994-12-08
AU6940594A (en) 1994-12-20
JPH08510731A (ja) 1996-11-12

Similar Documents

Publication Publication Date Title
JP2547726B2 (ja) フェンタニルの皮膚投与およびそのための装置
US5624962A (en) Aqueous drug composition having property of reversible thermosetting gelation
IT1261849B (it) Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
DE3681582D1 (de) Pharmazeutische zubereitung mit abgabeeigenschaften.
GB0015617D0 (en) Improved preparations for dermal delivery of active substances
CO5130022A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
EA200101026A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
CA2388610A1 (en) Oral transmucosal drug dosage using solid solution
WO2001085137A3 (en) Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GT199900151A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial.
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
ATE509616T1 (de) Topische pharmazeutische und/oder cosmetische dosierungssysteme
SE9301877D0 (sv) In situ gel for therapeutic use
ATE292453T1 (de) Antivirale arznei
ES2139842T3 (es) Uso de la melatonina para tratar a pacientes que sufren drogodependencia.
KR20230050475A (ko) 고농도 생물 발효 히알루론산 나트륨으로 구성된 국소성 중합체 기지 합성물 및 그 사용
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
WO2003101378A3 (en) Pharmaceutical formulation in a drug delivery system and process for preparing the same
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
AR012996A1 (es) Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use
US7658947B2 (en) Thermo-gelling composition
WO2023150579A3 (en) Pharmaceutical formulations containing nalbuphine